Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.
作者信息
Ateya Areej Mohamed, Sabri Nagwa A
机构信息
Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt.
出版信息
J Med Virol. 2021 Apr;93(4):1873-1874. doi: 10.1002/jmv.26672. Epub 2020 Nov 22.
Abstract
摘要
相似文献
1
Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers benefits outweigh the risks in COVID-19 hypertensive patients.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂对新冠肺炎高血压患者的益处大于风险。
J Med Virol. 2021 Apr;93(4):1873-1874. doi: 10.1002/jmv.26672. Epub 2020 Nov 22.
2
Update Alert 6: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报6：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2021 Jan;174(1):W17. doi: 10.7326/L20-1355. Epub 2020 Dec 1.
3
The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients.在新冠肺炎患者中使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂的争议。
J Renin Angiotensin Aldosterone Syst. 2021 Jan-Dec;22(1):1470320320987118. doi: 10.1177/1470320320987118.
4
Update Alert 5: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报5：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Dec 15;173(12):167-168. doi: 10.7326/L20-1293. Epub 2020 Oct 27.
5
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报4：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对新型冠状病毒感染的风险及影响
Ann Intern Med. 2020 Nov 3;173(9):W147-W148. doi: 10.7326/L20-1177. Epub 2020 Sep 22.
6
The renin-angiotensin-aldosterone system inhibitor dilemma in COVID-19: balancing cardiovascular benefits and viral risks.新型冠状病毒肺炎中肾素-血管紧张素-醛固酮系统抑制剂的困境：权衡心血管益处与病毒风险
Hypertens Res. 2024 Sep;47(9):2598-2600. doi: 10.1038/s41440-024-01772-x. Epub 2024 Jul 1.
7
Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic.在2019冠状病毒病大流行期间，使用血管紧张素II受体阻滞剂或血管紧张素转换酶抑制剂治疗高血压。
Expert Rev Cardiovasc Ther. 2021 Jan;19(1):99-100. doi: 10.1080/14779072.2021.1842050. Epub 2020 Nov 12.
8
Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.最新警报9：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对2019冠状病毒病感染的风险及影响
Ann Intern Med. 2022 Apr;175(4):W47-W48. doi: 10.7326/L21-0791. Epub 2022 Feb 8.
9
Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.更新警报10：成人中血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对严重急性呼吸综合征冠状病毒2感染的风险及影响
Ann Intern Med. 2023 May;176(5):eL230049. doi: 10.7326/L23-0049. Epub 2023 Mar 21.
10
Antihypertensive Drugs and COVID-19 Risk: A Cohort Study of 2 Million Hypertensive Patients.抗高血压药物与 COVID-19 风险：一项涉及 200 万高血压患者的队列研究。
Hypertension. 2021 Mar 3;77(3):833-842. doi: 10.1161/HYPERTENSIONAHA.120.16314. Epub 2021 Jan 11.
本文引用的文献
1
The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis.血管紧张素转化酶抑制剂（ACEI）和血管紧张素Ⅱ受体拮抗剂（ARB）类药物的使用与高血压合并 COVID-19 患者的死亡率降低相关：系统评价和荟萃分析。
J Med Virol. 2021 Mar;93(3):1370-1377. doi: 10.1002/jmv.26625. Epub 2020 Nov 10.
2
2020 update on the renin-angiotensin-aldosterone system in pediatric kidney disease and its interactions with coronavirus.2020年小儿肾脏疾病中肾素-血管紧张素-醛固酮系统及其与冠状病毒相互作用的最新进展
Pediatr Nephrol. 2021 Jun;36(6):1407-1426. doi: 10.1007/s00467-020-04759-1. Epub 2020 Sep 29.
3
Pathological Role of Angiotensin II in Severe COVID-19.血管紧张素II在重症新型冠状病毒肺炎中的病理作用
TH Open. 2020 Jun 26;4(2):e138-e144. doi: 10.1055/s-0040-1713678. eCollection 2020 Apr.
4
Endothelial cell infection and endotheliitis in COVID-19.新型冠状病毒肺炎中的内皮细胞感染与内皮炎
Lancet. 2020 May 2;395(10234):1417-1418. doi: 10.1016/S0140-6736(20)30937-5. Epub 2020 Apr 21.
5
Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.基于对来自中国武汉的150名患者数据的分析得出的COVID-19相关死亡的临床预测因素。
Intensive Care Med. 2020 May;46(5):846-848. doi: 10.1007/s00134-020-05991-x. Epub 2020 Mar 3.
6
Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation.不同类别降压药对血管内皮功能和炎症的影响。
Int J Mol Sci. 2019 Jul 14;20(14):3458. doi: 10.3390/ijms20143458.
7
Angiotensin converting enzyme inhibitors effect on endothelial dysfunction: a meta-analysis of randomised controlled trials.血管紧张素转换酶抑制剂对血管内皮功能障碍的影响：一项随机对照试验的荟萃分析。
Atherosclerosis. 2011 May;216(1):7-16. doi: 10.1016/j.atherosclerosis.2011.02.044. Epub 2011 Feb 26.
8
Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade.血管紧张素II与炎症：血管紧张素转换酶抑制和血管紧张素II受体阻断的作用
J Hum Hypertens. 2007 Jan;21(1):20-7. doi: 10.1038/sj.jhh.1002101. Epub 2006 Nov 9.
9
Potential Antithrombotic and Fibrinolytic Properties of the Angiotensin Converting Enzyme Inhibitors.血管紧张素转换酶抑制剂的潜在抗血栓形成和纤维蛋白溶解特性。
J Thromb Thrombolysis. 1995;1(3):251-257. doi: 10.1007/BF01060734.
10
The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats.卡托普利和氯沙坦对大鼠实验性动脉血栓形成的抗血栓作用。
J Physiol Pharmacol. 1998 Jun;49(2):251-60.
Zotero 插件